Nasdaq, S&P 500, Dow Jones poised to open on Monday, as investors await to see the ripple effect of a global stock market ...

Nasdaq, S&P 500, Dow Jones poised to open on Monday, as investors await to see the ripple effect of a global stock market ...

A key theme at the AD/PD 2025 has been the safety profile of DMTs, focusing on the issue of ARIA, a significant side effect of the Aβ mAb drug class.

Sarepta and Roche will share the monitors' findings with EMA to resolve a temporary hold. Elsewhere, Allakos agreed to a buyout and high-dose Ocrevus missed a study goal.

Weight loss drugs such as semaglutide, found in Ozempic and Wegovy, are tied to a 40% reduced risk of an Alzheimer's disease diagnosis. On Wednesday, a study in Nature suggested that a vaccine for ...

DAX hits February low as trade war risks escalate; forecast eyes trade progress, US jobs data, and Fed Chair Powell’s remarks ...

Given the calls for change, criticism, and ongoing consultations, this article sets out the current status of developments ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...

This article examines post-market drug safety, highlighting surveillance mechanisms, regulatory responses, and case studies of approved drugs with hidden risks.

Akebia Therapeutics gets EMA panel support for Xoanacyl to treat high phosphate & iron deficiency in CKD. Read more here.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) fell in the premarket on Thursday following news regarding a clinical hold ...